Gradient

Product Stewardship and Safety

Endocrine Disrupting Chemicals

Overview
Example Projects
Experts

Overview

The issue of endocrine disruption has become an important focus of environmental and human health science.  Results from the US EPA's Endocrine Disruptor Screening Program (EDSP) are likely to form the basis of future regulation of endocrine disrupting chemicals in the US, while regulatory initiatives are also underway in the EU and Japan.  Gradient's experts have been closely involved in research and priority setting for the regulatory screening and testing of endocrine disruptors. Our staff also lend their expertise to the ongoing interpretation of scientific evidence regarding endocrine disruption as a potential public health problem, which has included presenting analyses and weight-of-evidence approaches on the evaluation of endocrine-mediated effects at international meetings aiming to formulate science policies.

Example Publications:

Rhomberg, LR; Goodman, JE. 2012. "Low-dose effects and nonmonotonic dose-responses of endocrine disrupting chemicals: Has the case been made?" Reg. Tox. Pharmacol. 64(1):130-133.

Verslycke, T; Ghekiere, A; Raimondo, S; Janssen, CR. 2007. "Mysid crustaceans as standard models for the screening and testing of endocrine-disrupting chemicals." Ecotoxicol. 16(1):205-219.

Verslycke, T; Fockedey, N; McKenney, CL; Roast, SD; Jones, MB; Mees, J; Janssen, CR. 2004. "Mysids as potential test organisms for the evaluation of environmental endocrine disruption: A review." Environ. Toxicol. Chem. 23(5):1219-1234.

Example Projects

Integrated Summary Report for US EPA's EDSP

Full Description

Gradient served as author and lead technical expert on the Integrated Summary Report of the Invertebrate (Mysid) Two-Generation Toxicity Test being proposed as a Tier 2 testing assay under US EPA's Endocrine Disruptor Screening Program (EDSP).

Endocrine Disruption Assay Development

Full Description

To evaluate the estrogenic potency of hormonally active pharmaceutical ingredients (APIs) and better understand their potential impact on the aquatic environment, Gradient developed a new fish estrogen receptor (ER) in vitro binding assay. Aquatic species effect concentrations obtained using this assay were used to set effluent guidelines at pharmaceutical manufacturing facilities that are protective of aquatic receptors in the receiving environment.

Bisphenol A REACH Data Compilation

Full Description

Gradient reviewed scientific studies of Bisphenol A and compiled the information into the toxicity section of IUCLID 5 (International Uniform ChemicaL Information Database), an electronic repository for the intrinsic and hazard properties of chemical substances for the European Union (EU) REACH regulation.

Bisphenol A Weight-of-Evidence Review

Full Description

Gradient conducted a comprehensive critical weight-of-evidence review of studies bearing on the ability of very low bisphenol A (BPA) exposures to affect reproduction and development in mammals via endocrine disruption.

Endocrine Disruption Assessments and Issues

Full Description

Gradient led a team of international experts in production of a paper, for the European Commission, that critically evaluated a state-of-the-art assessment of endocrine disruption.  Gradient also played a key role in a review and an evaluation of an assessment of endocrine disruption science produced for the WHO/IPCS.

Experts

Julie E. Goodman Read Bio

David B. Mayfield Read Bio

Lorenz R. Rhomberg Read Bio

Tim Verslycke Read Bio